# European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)

> **NCT01260870** · PHASE2 · TERMINATED · sponsor: **Bayer** · enrollment: 44 (actual)

## Conditions studied

- PAD
- Infrapopliteal Lesions

## Interventions

- **DEVICE:** Cotavance Paclitaxel Coated Balloon
- **DEVICE:** Standard balloon angioplasty

## Key facts

- **NCT ID:** NCT01260870
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08-15
- **Primary completion:** 2013-07-15
- **Final completion:** 2013-07-15
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** Bayer terminated the program and sold the IP to Medronic
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01260870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01260870, "European Study of POBA Versus Cotavance(R) Paclitaxel Coated Balloon for the Treatment of Infrapopliteal Lesions in Critical Limb Ischemia (EURO CANAL)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01260870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*